These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23065705)

  • 21. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
    Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
    Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
    Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
    Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.
    Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P
    J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of physiologic actions of LRRK2: focus on autophagy.
    Ferree A; Guillily M; Li H; Smith K; Takashima A; Squillace R; Weigele M; Collins JJ; Wolozin B
    Neurodegener Dis; 2012; 10(1-4):238-41. PubMed ID: 22204929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
    Dusonchet J; Li H; Guillily M; Liu M; Stafa K; Derada Troletti C; Boon JY; Saha S; Glauser L; Mamais A; Citro A; Youmans KL; Liu L; Schneider BL; Aebischer P; Yue Z; Bandopadhyay R; Glicksman MA; Moore DJ; Collins JJ; Wolozin B
    Hum Mol Genet; 2014 Sep; 23(18):4887-905. PubMed ID: 24794857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
    Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
    Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.
    Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW
    Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2.
    Hsu CH; Chan D; Greggio E; Saha S; Guillily MD; Ferree A; Raghavan K; Shen GC; Segal L; Ryu H; Cookson MR; Wolozin B
    J Neurochem; 2010 Mar; 112(6):1593-604. PubMed ID: 20067578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.